Company Overview
| Stock Name | Hygeia Health |
|---|---|
| Stock Code | 06078 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 以腫瘤科為核心的醫療集團,主要經營自有民營營利性醫院並提供腫瘤醫療服務及其他醫療服務;提供放療中心諮詢服務、專利立體定向放療設備授權及維護和技術支持服務;以及管理民營非營利性醫院並收取管理費。 |
| Listing Date | 2020-06-29 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市靜安區梅園路228號企業廣場702-707室 |
| Business Address (Hong Kong) | 香港灣仔皇后大道東248號陽光中心40樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.hygeia-group.com.cn |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 18.50 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 200 shares |
| Entry Threshold | HK$ 3,700 |
| Par Value | To be extracted |
| Offer Period | 2020-06-16 to 2020-06-19 |
| Global Offering Shares | 120,000,000 shares |
| HK Public Offer Shares (Initial) | 12,000,000 shares (10.0%) |
| Public Offer Lots (Initial) | 60,000lots (Pool A30,000lots,Pool B30,000lots) |
| International Placing Shares (Initial) | 108,000,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 600,000,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 49.9% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 2,220,000,000 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 200 | HK$ 3,700 |
| 2 lots | 400 | HK$ 7,400 |
| 3 lots | 600 | HK$ 11,100 |
| 4 lots | 800 | HK$ 14,800 |
| 5 lots | 1,000 | HK$ 18,500 |
| 6 lots | 1,200 | HK$ 22,200 |
| 7 lots | 1,400 | HK$ 25,900 |
| 8 lots | 1,600 | HK$ 29,600 |
| 9 lots | 1,800 | HK$ 33,300 |
| 10 lots | 2,000 | HK$ 37,000 |
| 15 lots | 3,000 | HK$ 55,500 |
| 20 lots | 4,000 | HK$ 74,000 |
| 25 lots | 5,000 | HK$ 92,500 |
| 30 lots | 6,000 | HK$ 111,000 |
| 35 lots | 7,000 | HK$ 129,500 |
| 40 lots | 8,000 | HK$ 148,000 |
| 45 lots | 9,000 | HK$ 166,500 |
| 50 lots | 10,000 | HK$ 185,000 |
| 100 lots | 20,000 | HK$ 370,000 |
| 150 lots | 30,000 | HK$ 555,000 |
| 200 lots | 40,000 | HK$ 740,000 |
| 250 lots | 50,000 | HK$ 925,000 |
| 300 lots | 60,000 | HK$ 1,110,000 |
| 350 lots | 70,000 | HK$ 1,295,000 |
| 400 lots | 80,000 | HK$ 1,480,000 |
| 450 lots | 90,000 | HK$ 1,665,000 |
| 500 lots | 100,000 | HK$ 1,850,000 |
| 1,000 lots | 200,000 | HK$ 3,700,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,500 lots | 300,000 | HK$ 5,550,000 |
| 2,000 lots | 400,000 | HK$ 7,400,000 |
| 2,500 lots | 500,000 | HK$ 9,250,000 |
| 3,000 lots | 600,000 | HK$ 11,100,000 |
| 3,500 lots | 700,000 | HK$ 12,950,000 |
| 4,000 lots | 800,000 | HK$ 14,800,000 |
| 4,500 lots | 900,000 | HK$ 16,650,000 |
| 5,000 lots | 1,000,000 | HK$ 18,500,000 |
| 10,000 lots | 2,000,000 | HK$ 37,000,000 |
| 15,000 lots | 3,000,000 | HK$ 55,500,000 |
| 20,000 lots | 4,000,000 | HK$ 74,000,000 |
| 25,000 lots | 5,000,000 | HK$ 92,500,000 |
| 30,000 lots | 6,000,000 | HK$ 111,000,000 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 6.59B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 10,650,000,000 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣39.8百萬元 |
| Period-End Cash Balance | 人民幣393.4百萬元 |
| Listing Expenses | ~HK$ 144,200,000 |
| Listing Expenses / Funds Raised | ~6.5% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2017 | 2018 | 2019 |
|---|---|---|---|
| Revenue | 596,480 | 766,142 | 1,085,826 |
| Cost of sales | -427,172 | -527,407 | -755,706 |
| Gross profit | 169,308 | 238,735 | 330,120 |
| Other income and gains, net | 3,772 | 4,150 | 4,895 |
| Selling and distribution expenses | -34,713 | -32,781 | -15,419 |
| Administrative expenses | -97,504 | -101,574 | -136,272 |
| Operating profit | 48,387 | 105,542 | 174,207 |
| Net finance costs | -73,126 | -78,279 | -94,887 |
| Profit before tax | -24,739 | 27,263 | 79,320 |
| Income tax expense | -21,771 | -24,845 | -39,553 |
| Profit for the year | -46,510 | 2,418 | 39,767 |
| Profit attributable to owners | -46,434 | 2,588 | 39,767 |
Balance Sheet
| Item | 2017 | 2018 | 2019 |
|---|---|---|---|
| Cash and cash equivalents | 280,660 | 190,552 | 393,409 |
| Trade and bills receivables | 152,177 | 225,068 | 224,936 |
| Inventories | 35,330 | 41,017 | 47,016 |
| Total current assets | 562,118 | 513,104 | 668,530 |
| Total assets | 1,783,592 | 1,982,490 | 2,213,189 |
| Total current liabilities | 393,004 | 415,446 | 1,714,181 |
| Total liabilities | 2,086,455 | 2,170,734 | 2,415,795 |
| Total equity | -302,863 | -188,244 | -202,606 |
| Equity attributable to owners | -306,655 | -191,866 | -202,606 |
| Interest-bearing borrowings | 66,000 | 56,000 | 0 |
Cash Flow Statement
| Item | 2017 | 2018 | 2019 |
|---|---|---|---|
| Net cash from operating activities | 66,825 | 159,941 | 228,617 |
| Net cash from investing activities | 84,198 | -262,462 | -134,978 |
| Net cash from financing activities | -47,301 | 12,397 | 104,562 |
| Net increase in cash | 103,722 | -90,124 | 198,201 |
| Purchase of PP&E | -229,285 | -287,647 | -154,245 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 26.0 |
|---|---|
| First Day Open | HK$ 22.8 |
| First Day Change | 40.54% |
| First Day Volume | 78681000.0 |
| First Day Turnover | 1913350000.0 |
| Use of Proceeds | 1、約60%(或1,243.3百萬港元)將用于單縣海吉亞醫院、重慶海吉亞醫院及成武海吉亞醫院(均屬我們的自有營利性醫院)的升級,并在聊城、德州、蘇州及龍巖市設立新醫院;
2、約30%(或621.7百萬港元)將用于合適機遇到來時,在人口龐大、對腫瘤醫療服務需求相對較高的新市場中收購醫院;
3、約5%(或103.6百萬港元)將用于升級信息技術系統;
4、約5%(或103.6百萬港元)將用于營運資金及其他一般企業用途。 |
Underwriting Syndicate
Overall Coordinators (3)
Joint Bookrunners (3)
Joint Lead Managers (3)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Foresight Orient Global Superior Choice SPC | 38,746,400 HKD | — | 1.75% | — | 6 months | 2020-12-29 |
| 2 | Golden Valley Global Limited | 38,746,400 HKD | — | 1.75% | — | 6 months | 2020-12-29 |
| 3 | Hillhouse Funds | 387,493,600 HKD | — | 17.45% | — | 6 months | 2020-12-29 |
| 4 | Hudson Bay Master Fund LTD | 77,496,500 HKD | — | 3.49% | — | 6 months | 2020-12-29 |
| 5 | Lake Bleu Prime Healthcare Master Fund Limited | 92,995,800 HKD | — | 4.19% | — | 6 months | 2020-12-29 |
| 6 | OrbiMed Funds | 154,996,700 HKD | — | 6.98% | — | 6 months | 2020-12-29 |
| 7 | Sage Partners Master Fund | 77,496,500 HKD | — | 3.49% | — | 6 months | 2020-12-29 |
| 8 | Tiger Pacific Master Fund LP | 123,998,100 HKD | — | 5.59% | — | 6 months | 2020-12-29 |
| 9 | 南方基金管理股份有限公司 | 116,246,600 HKD | — | 5.24% | — | 6 months | 2020-12-29 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 方敏 | — |
| Company Secretary | 任愛、楊靜文 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 朱先生及朱女士一致行動人士透過Century River、Red Palm及Amber Tree持有約46.46%股權;Fountain Grass持有約13.79%;Harmony Healthcare持有約6.20%。 |
|---|




